Stock listing
Neuren Pharmaceuticals Limited
Selected listing: NK9 · FWB · EUR · DE
Neuren Pharmaceuticals Limited (Frankfurt:NK9), Health Technology. Latest release Sep 29, 2026: Trofinetide US patent protections extended to March 2041.
- Ticker
- Frankfurt:NK9
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Generic
- Exchange
- Frankfurt
- Currency
- EUR
About Neuren Pharmaceuticals Limited
The company focuses on developing innovative therapies for neurological disorders. Neuren is committed to advancing its research and development efforts to address unmet medical needs in this area.
Latest news from Neuren Pharmaceuticals Limited
Trofinetide US patent protections extended to March 2041
September 28, 2026
Growing royalty anchors Neuren first ever dividend program
August 25, 2026
European Commission grants marketing authorisation for DAYBU
August 24, 2026
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
August 4, 2026
DAYBU recommended for approval in the European Union
June 28, 2026
Research Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited company profile
View the public company page for Neuren Pharmaceuticals Limited on 6ix.
Neuren Pharmaceuticals Limited news
Read company news and market updates connected to Neuren Pharmaceuticals Limited.
Neuren Pharmaceuticals Limited investor events
Find investor webinars, events, and replay context for Neuren Pharmaceuticals Limited.
Alternate listings
NEU:ASX
AU · AUD
Alternate listing for Neuren Pharmaceuticals Limited; the primary context on this page is NK9:FWB.
NURPF:OTC
US · USD
Alternate listing for Neuren Pharmaceuticals Limited; the primary context on this page is NK9:FWB.
NK9:SWB
DE · EUR
Alternate listing for Neuren Pharmaceuticals Limited; the primary context on this page is NK9:FWB.